JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case Report

Springer Science and Business Media LLC - Tập 43 - Trang 1766-1769 - 2023
Amir Abdelmoumen1,2,3,4, Joris van Montfrans2,4, Femke van Wijk3,4, Helen Leavis1,4
1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
2Department of Pediatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
3Division Laboratories, Pharmacy and Biomedical Genetics, Center for Translational Immunology (CTI), University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
4University Medical Center Utrecht, Utrecht, The Netherlands

Tài liệu tham khảo

Strohmeier V, Andrieux G, Unger S, Pascual-Reguant A, Klocperk A, Seidl M, et al. Interferon-driven immune dysregulation in common variable immunodeficiency-associated villous atrophy and norovirus infection. J Clin Immunol. 2023;43(2):371–90. van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810–4. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385(3):228–38. Mannon PJ, Fuss IJ, Dill S, Friend J, Groden C, Hornung R, et al. Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology. 2006;131(3):748–56. Jorgensen SF, Reims HM, Frydenlund D, Holm K, Paulsen V, Michelsen AE, et al. A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency. Am J Gastroenterol. 2016;111(10):1467–75.